Linagliptin Pharos

Linagliptin, the active ingredient in Linagliptin Pharos, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and other antidiabetic agents are insufficient.

GNH USA supplies Linagliptin Pharos as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Shipments are managed through reliable logistics networks.

Linagliptin Pharos is a DPP-4 inhibitor used in the treatment of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): improves glycemic control in adults when diet and exercise are insufficient. - Type 2 diabetes mellitus (combination therapy): added to metformin, sulfonylureas, or insulin to achieve target HbA1c. - Type 2 diabetes mellitus (renal impairment): can be used without dose adjustment in patients with mild to moderate renal impairment.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient, usually mild. - Upper respiratory tract infection: symptoms of cough and congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: including angioedema or Stevens‑Johnson syndrome. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: rare autoimmune skin disorder. - Acute renal failure: very rare, monitor renal function if symptoms arise.

Linagliptin should be used with clinical oversight and patient-specific considerations. - Renal function: no dose adjustment needed, but monitor in severe impairment. - Hepatic function: use with caution in moderate hepatic disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Drug interactions: review concomitant medications for potential effects. - Store at ambient temperature: keep in original container, protect from moisture and light.

Linagliptin may interact with several concomitant medicines; monitoring is advised.

Major Interactions (Avoid): - Co‑administration with other DPP‑4 inhibitors: risk of additive effects. - Strong P‑gp inhibitors (e.g., itraconazole): may increase linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Metformin: monitor for lactic acidosis, especially in renal impairment. - Sulfonylureas or insulin: increased risk of hypoglycemia. - Rifampin: may reduce linagliptin exposure, affecting glycemic control.